Abstract CT040: Updated overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (mUC) in IMvigor130

Background: In the IMvigor130 primary analysis in patients (pts) with untreated locally advanced or mUC, a trend toward favorable OS with atezo (anti-PD-L1) monotherapy (Arm B) vs placebo + platinum/gemcitabine (plt/gem; Arm C) was seen in pts with PD-L1-expressing immune cells on ≥5% of the tumor a...

Full description

Bibliographic Details

Published in:	Cancer research (Chicago, Ill.) Vol. 81; no. 13_Supplement; p. CT040
Main Authors:	Davis, Ian D., Galsky, Matthew D., Garcia del Muro, Xavier, Park, Se Hoon, De Giorgi, Ugo, Alekseev, Boris, Mencinger, Marina, Izumi, Kouji, Puente, Javier, Li, Jian-Ri, Arranz, José Ángel, Bamias, Aristotelis, Grande, Enrique, Kikuchi, Eiji, Mecke, Almut, Mariathasan, Sanjeev, Shen, Xiaodong, Huang, Hannah (Xinhui), De Santis, Maria
Format:	Journal Article
Language:	English
Published:	01-07-2021
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!